Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.62 |
| ▸ | SNCA | P37840 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492489 | 0.85 | TRPV1 (0.83) | TRPV1KMT2AMEN1POLBLMNA | |
| SCHEMBL23925693 | 0.85 | GOT1 (0.64) | MTNR1AMTNR1BTRPV1SNCAKMT2A | |
| SCHEMBL5341652 | 0.83 | MEN1 (0.73) | MTNR1AMTNR1BTRPV1SNCAKMT2A | |
| SCHEMBL4330537 | 0.81 | MTNR1A (0.60) | MTNR1AMTNR1BTRPV1SNCAKMT2A | |
| SCHEMBL11080741 | 0.79 | MTNR1A (0.78) | MTNR1AMTNR1BKMT2AMEN1POLB | |
| SCHEMBL6919750 | 0.78 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL9935196 | 0.77 | SNCA (0.85) | TRPV1SNCAMAPT | |
| SCHEMBL4327005 | 0.76 | MTNR1A (0.65) | MTNR1AMTNR1BTRPV1SNCAKMT2A | |
| SCHEMBL4325288 | 0.75 | MTNR1A (0.61) | MTNR1AMTNR1BTRPV1SNCAKMT2A | |
| SCHEMBL15313062 | 0.75 | SNCA (1.00) | SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | disclosed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | TLR4, TLR5, TLR1 | MTNR1A 1499/4885MTNR1B 1258/4885TRPV1 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.